Faculty Opinions recommendation of Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.

2017 ◽  
Author(s):  
Shwu-Jiuan Sheu ◽  
Shih-Chou Chen
Keyword(s):  
Posterior Uveitis ◽  
Fluocinolone Acetonide ◽  
Steroid Treatment ◽  
Intermediate Uveitis ◽  
Follow Up Study ◽  
Intraocular Implant ◽  
Anti Inflammatory

Systemic Anti-Inflammatory Therapy Versus Fluocinolone Acetonide

2020 ◽  
pp. 263-268
Author(s):  
Alan D. Penman ◽  
Kimberly W. Crowder ◽  
William M. Watkins
Keyword(s):  
Comparative Effectiveness ◽  
Cost Effective ◽  
Initial Therapy ◽  
Posterior Uveitis ◽  
Fluocinolone Acetonide ◽  
Intermediate Uveitis ◽  
Systemic Corticosteroids ◽  
Active Intermediate ◽  
Implant Therapy

The Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study was a randomized, partially-masked, parallel treatment, comparative effectiveness trial comparing surgically placed fluocinolone acetonide intravitreous implant to systemic corticosteroids for the treatment of intermediate uveitis, posterior uveitis, and panuveitis. Systemic and implant therapies yielded similar visual outcomes through 54 months of treatment. Given the greater cost of implant therapy for bilateral disease, and the higher risk of ocular complications in the implant arm of the trial, systemic therapy may be the preferred initial therapy for most bilateral cases of active or recently active intermediate uveitis, posterior uveitis, and panuveitis. For unilateral cases, implant therapy seemed to be reasonably cost effective.

scholarly journals Dissociations of the Fluocinolone Acetonide Implant: The Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study

2016 ◽  
Vol 164 ◽  
pp. 29-36 ◽  
Author(s):  
Janet T. Holbrook ◽  
Elizabeth A. Sugar ◽  
Alyce E. Burke ◽  
Albert T. Vitale ◽  
Jennifer E. Thorne ◽  
...  
Keyword(s):  
Fluocinolone Acetonide ◽  
Steroid Treatment ◽  
Follow Up Study ◽  
Fluocinolone Acetonide Implant

scholarly journals Outcomes from a Multi-disciplinary Uveitis Referral Clinic in Tasmania, Australia and adaptation during the COVID-19 pandemic

2021 ◽  
Author(s):  
Verlyn Yang
Keyword(s):  
Case Series ◽  
Developed Countries ◽  
Posterior Uveitis ◽  
Indigenous Populations ◽  
Published Data ◽  
Inflammatory Disorder ◽  
Intermediate Uveitis ◽  
Retrospective Case ◽  
Common Causes

Abstract Background: Uveitis is one of the most common causes of visual impairment, accounting for up to 25% of visual loss in the developing world and 10% in developed countries. There are marked regional differences within Australia, particularly in rural and Indigenous populations. There is no published data on uveitis in Tasmania. Methods: A 5-year retrospective case series review of medical records of all patients reviewed to the clinic was performed. Results: A total of 95 patients were referred to the clinic. Seventy-six (76) patients (123 eyes) had uveitis and were analysed in detail (see table 1). Nineteen (19) patients had a diagnosis other than uveitis or were on immunosuppressive therapy for another ocular inflammatory disorder (detailed in Table 2). The most common anatomical diagnosis was posterior uveitis (29%), followed by pan-uveitis (20%) and intermediate uveitis (17%). Average follow-up was 36.7 months. Conclusion: The most common anatomical diagnosis was posterior uveitis (29%), followed by pan-uveitis (20%) and intermediate uveitis (17%). Telemedicine is a modality that could have application in management of Uveitis in regional areas.

Sign in / Sign up

Export Citation Format

Share Document